Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.

This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.

Colleagues from all over the world have shared loving tributes to Braunwald. ESC President Thomas F. Lüscher, MD, called him "the pioneering cardiologist of his time."

Cardiac complications after noncardiac surgeries are a significant concern, especially as patients keep living longer and surgical volumes continue to rise.

There is a belief among some clinicians that it is too easy for companies to gain CE mark approval for their medical devices. However, a new proposal from the European Society of Cardiology and other groups could help change that. 

When patients present with STEMI-related cardiogenic shock, treatment with the Impella CP appears to make a positive impact that lasts for at least a decade.

The European Society of Cardiology had nearly twice as many attendees as ACC this year, as the European meeting secures its place as the largest cardiology meeting in the world.

The Varipulse PFA platform, which has already received FDA and CE mark approval, was linked to an adverse event rate of just 0.6%.